Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment

por Qin, Albert
Publicado 2023

An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1

por Qin, Albert
Publicado 2023

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

por Huang, Yi-Wen, Qin, Albert, Tsai, Chan-Yen, Chen, Pei-Jer
Publicado 2022

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives...

por Qin, Albert, Urbanski, Raymond W., Yu, Lennex, Ahmed, Tasfia, Mascarenhas, John
Publicado 2023

Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results

por Hong, Jin-Bon, Wu, Po-Yuan, Qin, Albert, Huang, Yi-Wen, Tseng, Kuan-Chiao, Lai, Ching-Yu, Chan, Wing-Kai, Fang, Jane, Cutler, David L., Tsai, Tsen-Fang
Publicado 2022

Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan

por Chen, Kuan-Yuan, Lee, Kang-Yun, Qin, Albert, Luo, Ching-Shan, Yeh, Yun-Kai, Zheng, Jing-Quan, Chen, Ching-Mei, Tsai, Chan-Yen, Lin, Sheena, Liao, Jason, Huang, Yi-Wen, Feng, Po-Hao
Publicado 2021

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

por Huang, Yi-Wen, Hsu, Chao-Wei, Lu, Sheng-Nan, Yu, Ming-Lung, Su, Chien-Wei, Su, Wei-Wen, Chien, Rong-Nan, Hsu, Ching-Sheng, Hsu, Shih-Jer, Lai, Hsueh-Chou, Qin, Albert, Tseng, Kuan-Chiao, Chen, Pei-Jer
Publicado 2020

Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study

por Dai, Ming-Shen, Chao, Ta-Chung, Chiu, Chang-Fang, Lu, Yen-Shen, Shiah, Her-Shyong, Jackson, Christopher G. C. A., Hung, Noelyn, Zhi, Jianguo, Cutler, David L., Kwan, Rudolf, Kramer, Douglas, Chan, Wing-Kai, Qin, Albert, Tseng, Kuan-Chiao, Hung, Cheung Tak, Chao, Tsu-Yi
Publicado 2023

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy

por Lin, Hsien‐Hong, Hsu, Shih‐Jer, Lu, Sheng‐Nan, Chuang, Wan‐Long, Hsu, Chao‐Wei, Chien, Rong‐Nan, Yang, Sien‐Sing, Su, Wei‐Wen, Wu, Jaw‐Ching, Lee, Tzong‐Hsi, Peng, Cheng‐Yuan, Tseng, Kuan‐Chiao, Qin, Albert, Huang, Yi‐Wen, Chen, Pei‐Jer
Publicado 2021

A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera

por Jin, Jie, Zhang, Lei, Qin, Albert, Wu, Daoxiang, Shao, Zonghong, Bai, Jie, Chen, Suning, Duan, Minghui, Zhou, Hu, Xu, Na, Zhang, Sujiang, Zuo, Xuelan, Du, Xin, Wang, Li, Li, Pei, Zhang, Xuhan, Li, Yaning, Zhang, Jingjing, Wang, Wei, Shen, Weihong, Zagrijtschuk, Oleh, Urbanski, Raymond, Sato, Toshiaki, Xiao, Zhijian
Publicado 2023

A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C

por Chen, Chi‐Yi, Chuang, Wan‐Long, Qin, Albert, Zhang, Wen‐Hua, Zhu, Li‐Ying, Zhang, Guo‐Qiang, Chen, Jyh‐Jou, Lo, Ching‐Chu, Zhou, Xinmin, Mao, Xiaorong, Shang, Jia, Kuo, Hsing‐Tao, Xie, Wen, Chen, Chien‐Hung, Lo, Gin‐Ho, Jun, Dae W, Dang, Shuangsuo, Tsai, Chan‐Yen, Wang, Ting‐Fang, Lai, Hsin‐Hui, Tseng, Kuan‐Chiao, Huang, Yi‐Wen, Chen, Pei‐Jer
Publicado 2022